Volume 31, Issue 8 , Pages 1502-1505, August 2005
CustomCornea wavefront retreatment after conventional laser in situ keratomileusis
Purpose
To evaluate the safety and efficacy of performing laser in situ keratomileusis (LASIK) retreatment using the Alcon CustomCornea system in patients who had prior myopic LASIK using conventional (nonwavefront) software.
Setting
Private practice ophthalmology clinic, St. Paul, Minnesota, USA.
Methods
In this prospective interventional trial, consecutive patients having CustomCornea retreatment following conventional LASIK were evaluated. Main outcome measures were uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA), refractive error, and higher-order aberrations (HOAs).
Results
Fourteen eyes of 10 patients were evaluated, with a mean follow-up of 5.3 months (range 6.2 to 15.4 months). Mean UCVA improved from 20/50 (logMAR) to 20/26 (P<.001). Mean spherical equivalent changed from −1.45 diopters (D) to +0.52 (P<.00001). Total aberrations, HOAs, defocus, and spherical aberration improved significantly. No eye lost a line of BCVA; 4 eyes (28.6%) gained 1 line, and 1 eye (7.1%) gained 2 lines. Ten eyes (71.4%) were within 0.5 D of emmetropia. Four eyes were overcorrected by 1.00 to 2.00 D. Risk factors for overcorrection included increased HOAs, higher spherical aberration, and not using the surgeon's offset at the time of surgery.
Conclusions
Wavefront retreatment following conventional LASIK is safe and effective. Care must be taken when treating patients with higher amounts of total aberration, especially spherical aberration. Refractive results are closer to emmetropia when the surgeon's offset is used.
To access this article, please choose from the options below
Presented at the ASCRS Symposium on Cataract, IOL and Refractive Surgery, San Diego, California, USA, May 2004.Dr. Lane is a paid medical monitor for Alcon. No other author has a financial or proprietary interest in any material or method mentioned.Wavefront retreatment represents an off-label use of this technology.Ali R. Djalilian, MD, assisted with statistical analysis.
PII: S0886-3350(05)00170-7
doi:10.1016/j.jcrs.2005.01.018
© 2005 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.
Volume 31, Issue 8 , Pages 1502-1505, August 2005
